At a glance
ClinicalIndex Comparison RecordN/ACompleted· 774 enrolled
Drug / intervention
Fesoterodine +1 moredrug
Likely dose
Fesoterodine 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 13-Week, Single-Arm, Open-Label, Multicenter Study To Evaluate Refill Adherence And Satisfaction With Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder.
In Brief
An observational study evaluating Fesoterodine and Your Way for Overactive Bladder. Completed, enrolled 774 participants.
Detailed Summary
The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with a prescription for fesoterodine.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionNov 2010
TodayJul 2026
First PostedJul 22, 2009
Enrollment StartJul 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.9 years ago
Interventions
Fesoterodinedrug
Fesoterodine 4 mg and 8 mg QD
Your Waybehavioral
early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB